Prevalence of Osteoporosis in Sickle Cell Disease

About the study

Sickle cell disease is the most common single-gene disease in the world. Its prevalence is increasing in France, with patients’ life expectancy increasing into developed countries. It mainly affects populations originating from sub-Saharan Africa. Among the chronic bone complications associated with sickle cell disease, osteoporosis has previously been highlighted but remains a poorly known complication in this very particular context. A dedicated evaluation of osteoporosis and associated risk factors in sickle cell disease patients living in France may enable better bone management of these patients in the future, as this problem, specific to their disease, is likely to become more frequent as their life expectancy increases.

This is a prospective interventional and monocentric study whose objective is to describe the prevalence of osteoporosis in black patients with sickle cell disease in France

Study point of contact

MERLE Blandine
04 72 11 74 80
[email protected]
CHAPURLAT Roland, PU, PH
04 72 11 74 82
[email protected]

Locations

1 France site

Age

20 to 40 Years

Study type

Observational

Age

20 Years - 40 Years

Gender

All

Interventions

Other

Compensation

Unknown

participation requirements

Black-skinned men and women
Aged 20 to 40 years old
Sickle cell patients
Non-opposition to participate in the study

participation restrictions

Refusal to participate in the study
Hemoglobinopathy other than sickle cell disease
Severe or End Stage Renal Failure
Long-term corticosteroid therapy (>3 months)
History of solid cancer or malignant haemopathy
History of organ transplantation
Pregnant or breastfeeding woman
Psychiatric pathology seriously impeding understanding
Difficulty understanding oral French

Locations

  • Lyon, France, Hôpital Edouard Herriot, 69437 [Recruiting]
Last updated 2021-12-08